4-13*10^6 cells/ml
Trade Name
Casgevy
Suspension for infusion
Request Type
New Registration
Drug Type
Biological Drug
Approval Date
SFDA Approved Use
Casgevy is indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).
- Casgevy is indicated for the treatment of transfusion-dependent β-thalassemia (TDT) in patients 12 years and older.
- Casgevy is indicated for the treatment of transfusion-dependent β-thalassemia (TDT) in patients 12 years and older.